Esperion Therapeutics, Inc.

ESPR

US29664W1053

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
1.190 ^USD	-4.03%		+1.71%	-45.91%

Jul. 09	Esperion Therapeutics, Inc. - Special Call
Jul. 08	Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040	MT

Sector Update: Health Care Stocks Steady Premarket Monday

Published on 03/25/2024 at 09:18, updated on 03/25/2024 at 09:57

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. - Special Call	Jul. 09
Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040	Jul. 08	MT
Esperion Therapeutics, Inc. Appoints Craig Thompson to Board of Directors	Jul. 01	CI
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from S&P Pharmaceuticals Select Industry Index	Jun. 22	CI
Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10:40 AM	Jun. 09
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute	May. 12	MT
Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol	May. 12	RE
Esperion Therapeutics Enters License and Distribution Agreement with HLS Therapeutics	May. 08	CI
Esperion Therapeutics, Inc., Q1 2025 Earnings Call, May 06, 2025	May. 06
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis at R&D Day 2025	Apr. 24	CI
Eric Warren to Stepp Down as Chief Commercial Officer of Esperion Therapeutics, Inc., Effective as of April 18, 2025	Apr. 04	CI
Esperion Announces Board Changes	Apr. 01	CI
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia	Mar. 20	MT
Esperion Therapeutics, Inc. Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia	Mar. 20	CI
Esperion Therapeutics, Inc., Q4 2024 Earnings Call, Mar 04, 2025	Mar. 04
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Mar. 04	CI
Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement	Mar. 03	RE
Esperion Partners with CSL Seqirus to Commercialize NEXLIZOL and NEXLIZET in Australia	Mar. 03	CI
Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Feb. 13	RE
Esperion Therapeutics, Inc. - Special Call	Jan. 22
Esperion Therapeutics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM	Jan. 15
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) added to NASDAQ Biotechnology Index	Dec. 22	CI
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) added to S&P Pharmaceuticals Select Industry Index	Dec. 22	CI
Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt	Dec. 18	MT

Chart Esperion Therapeutics, Inc.

Duration

Period

ESPR: Dynamic Chart

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Employees

304

Sector

Pharmaceuticals

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company